How Many Sales Reps Do I Need to Hire for My Medical Device Company in 2027?

Two ways to size a medical device sales team

Almost every headcount debate in a device company collapses into two competing methods, and picking the wrong one is where plans go sideways. The first is coverage-based sizing: you count the addressable accounts in a geography and divide by how many an individual can realistically service. The second is capacity-based sizing: you start from the revenue gap and divide by productive output per ramped rep. They frequently produce different answers for the same business, and the difference between those two answers is the most useful diagnostic you will run all year.

Coverage-based sizing asks a physical question: how many hospitals, surgery centers, clinics, or labs exist in this territory, and how often must someone physically be in the building? In device sales, physical presence is not optional the way it is in software. If your product requires case coverage — a rep in the OR during the procedure — coverage math dominates everything else. A rep covering surgical cases can realistically support somewhere between 8 and 20 active surgeon users depending on case volume and travel radius, because each case eats two to five hours including setup, scrub-in, and turnover. Multiply that ceiling out and you get a hard capacity wall that no amount of quota pressure moves. For non-case-coverage products — capital equipment, diagnostics, non-implantable devices — the ratio loosens considerably, and a rep might carry 50 to 100 target accounts with 15 to 25 of them active at any time.

Capacity-based sizing asks a financial question: what does one fully ramped rep produce in net-new revenue per year, and how many of those do I need to close the gap? This is the method that keeps you honest about cost. It also forces you to separate two revenue streams that most device companies blend together on the P&L: the reorder and consumables base that recurs largely on its own, and the genuinely new business a field rep must go win. Blending them inflates the apparent productivity per rep and causes chronic under-hiring, because leadership sees "$2.2M per rep" when the rep actually only originated $700K of it.

The failure mode of pure coverage sizing is over-hiring into thin territories — you staff a map instead of a market, and end up with reps in geographies that cannot mathematically produce enough procedure volume to cover their cost. The failure mode of pure capacity sizing is under-hiring into dense ones — the math says four reps, but four humans physically cannot be in eleven operating rooms across three states on the same Tuesday morning. Run both. Where coverage says six and capacity says four, you have a productivity problem or a territory-design problem, and hiring the difference will not fix it. Where coverage says four and capacity says seven, your territories are too big and you are leaving revenue on the table by asking reps to triage rather than sell.

A third structural option sits underneath both methods and deserves explicit consideration before you post a single job req: hiring direct W-2 reps versus contracting independent distributors or 1099 manufacturer's representatives. Independent distributors carry existing surgeon relationships and cost you nothing until they sell, typically taking 20–35% commission on revenue with no base salary, no benefits, no car allowance, and no ramp risk. Direct reps cost $150K–$250K fully loaded in year one before producing much, but they sell only your product, follow your process, generate clean CRM data, and build enterprise value you own. Most early-stage device companies start distributor-heavy for cash-flow reasons and convert to direct as territories mature past roughly $1.5M–$2M in annual revenue, where the commission line starts exceeding what a salaried rep would cost.

Choosing your sizing method before you open a req

The decision between coverage-first and capacity-first is not philosophical. It follows from three properties of your product and market that you can answer in about ten minutes.

Does your product require case coverage or clinical presence at point of use? If yes, coverage math sets the floor and capacity math only tells you whether that floor is affordable. Orthopedic implants, electrophysiology, spine, and most surgical robotics fall here. If no — capital imaging, most diagnostics, facility-level equipment — capacity math leads and coverage becomes a travel-cost constraint rather than a headcount constraint.

What percentage of next year's revenue is contractually recurring? If 80–95% of your base reorders disposables on standing contracts, your net-new number is small relative to total revenue and your rep count should be sized to the small number, not the big one. If you sell capital equipment with a 5–10 year replacement cycle, essentially all of next year's revenue is net-new and your rep count scales almost linearly with the target.

How long is the buying cycle from first contact to first purchase order? Consumables and disposables in existing accounts can move in 60–120 days. New accounts requiring value-analysis committee approval typically run 6–12 months. Capital equipment tied to a hospital's annual capital budget cycle runs 12–24 months and is gated by when that budget opens, not by rep effort. Cycle length determines how far ahead of the revenue year you must hire, which is often the single most expensive mistake in device headcount planning.

Run the comparison before you write a job description, not after. Once a req is open and a hiring manager has a candidate they like, nobody re-litigates whether the role should exist.

The numbers behind each option

Here is the full arithmetic on a company I will size concretely so you can substitute your own figures.

Assume a device company at $20M in annual revenue targeting $26M next year. Ninety percent of the installed base reorders consumables and stays on contract, so roughly $18M carries forward without a rep originating anything. That leaves about $8M of net-new business the field must win to reach $26M. If a fully ramped territory rep originates $2M of new business per year at realistic attainment — not at quota, at *actual historical attainment*, which in most device organizations runs 75–90% of quota — that is four rep-years of pure capacity.

Four is not the answer, though, because rep-years are not the same as reps. Ramp in medical device runs 9 to 12 months and sometimes longer: product training, clinical training, hospital credentialing through a vendor management system like Reptrax or Vendormate, immunization records, background checks, and then the slow work of earning enough surgeon trust to be invited into a case. A rep who starts in January contributes perhaps 25% of a full year's output in that first calendar year. Six reps starting in January therefore deliver roughly 1.5 rep-years of production, not six.

Then attrition. Annual voluntary turnover in device field sales commonly runs 10–20%, higher in the first eighteen months and higher still in territories that were handed over cold. On a ten-person field team at 15%, you are replacing one and a half reps a year just to stand still — and each of those replacements restarts the 9–12 month ramp clock in a territory that was producing.

Net all of that and the honest answer for this company is five to seven territory reps, started early enough to be credentialed and productive before the revenue is counted on. Not four.

Fully loaded cost per rep. Budget $150K–$250K all-in for a territory rep in year one: base salary typically $70K–$110K, target commission bringing on-target earnings to $150K–$220K, plus employer taxes and benefits at roughly 25–30% of base, a car or mileage allowance of $8K–$15K, travel and expenses of $10K–$25K, credentialing and compliance costs, sample and demo inventory carrying cost, and CRM and enablement seat licenses. Senior reps and capital equipment specialists run $200K–$350K. Clinical specialists — often nurses or surgical techs who handle in-service training and case coverage without carrying a quota — typically cost 40–60% less than a quota-carrying rep and can support multiple territories.

Break-even per rep. The formula is fully loaded annual cost divided by gross margin percentage. At 60% gross margin and $200K loaded cost, a rep must originate $333K in revenue to cover themselves on a steady-state basis. But apply ramp: a rep with only three productive months in year one needs that $333K compressed into a quarter of the year, so first-year break-even is closer to $1.3M annualized run rate by the time they exit ramp. Against a $2M ramped output assumption, that rep turns profitable somewhere in months ten through fourteen. If your gross margin is 45% rather than 60% — common in commodity disposables — break-even jumps to $444K steady-state and the whole model gets tighter fast.

Portfolio math on the six-rep plan. Six reps at $200K is $1.2M of year-one selling cost. If they collectively originate the $8M of net-new at 60% margin, that is $4.8M of gross profit against $1.2M of cost — roughly a 4:1 return on the sales investment at steady state, and closer to 1:1 or worse in the first year because of ramp. That first-year drag is the real reason device companies under-hire: the P&L pain is immediate and the return arrives two to four quarters later.

Distributor comparison on the same numbers. A distributor taking 30% commission on $2M of territory revenue costs you $600K — three times the loaded cost of a direct rep at that volume. At $500K of territory revenue, the same distributor costs $150K, cheaper than a direct rep and with no fixed downside. The crossover sits roughly between $700K and $1M of annual territory revenue depending on your commission rate and loaded cost. Below it, distributors win on economics. Above it, direct reps win, and the gap widens every year the territory grows.

Cost of an unfilled territory. A territory producing $1.5M–$2.5M annually that sits vacant for a 6–12 month backfill cycle costs you $750K–$2.5M in foregone revenue, plus the relationship erosion that a competitor's rep is actively exploiting while your accounts go uncovered. This is why backfill hiring should start at the resignation, not after it — and why some device companies deliberately run one "floater" rep per region as living insurance.

Sequencing the hires so the revenue actually lands

Getting the number right and getting the timing wrong produces the same miss. Here is the sequence that works.

Work backward from the revenue year, not forward from today. If you need $8M of net-new recognized in calendar 2027 and your average new-account cycle is 12 months, pipeline for that revenue must be built starting in early 2026. Add 9–12 months of ramp before a new hire can build credible pipeline, and your first req should open roughly 18 months before the revenue year. Most companies open it three months before and then wonder why Q1 missed.

Hire in waves, not one batch. Commit to 60–70% of the calculated headcount in wave one, then gate the remaining 30–40% on a measurable pipeline milestone at month six — for example, wave-one reps collectively carrying 2.5x their combined annual net-new target in qualified pipeline. If that milestone hits, release wave two with confidence. If it misses, you have preserved several hundred thousand dollars and bought time to diagnose whether the problem is the reps, the territories, the product, or the price. Waving also protects your onboarding capacity: a single sales trainer and clinical educator can meaningfully ramp three to four new reps at once, not eight.

Sequence roles, not just headcount. In a coverage-heavy device business, the highest-leverage first hire is often not another quota carrier. If your existing reps are spending 40–50% of their week on case coverage and in-service training, adding one clinical specialist across three territories can return meaningful selling hours to reps you already pay for — frequently a cheaper path to the next $1M than a sixth quota carrier. Similarly, if you have three or more large IDN or GPO contracts, a single overlay national account manager handling contract negotiation and value-analysis committee navigation frees every territory rep in that network from administrative drag and prevents five of your own people from calling the same supply chain director.

Front-load credentialing. Credentialing through hospital vendor management systems is a hard external dependency with its own queue, and it routinely takes 30–90 days per facility. Start it the week an offer is signed, not on day one of employment, and run it in parallel with product training. Reps who finish product training but cannot enter the building are the most expensive idle asset in a device company.

Set ramped-quota schedules explicitly. A common structure: 0% of full quota in months one through three, 33% in months four through six, 66% in months seven through nine, and 100% from month ten. Put the schedule in the offer letter. Reps who are held to full quota during ramp churn at dramatically higher rates, which restarts the entire clock and converts your hiring plan into a treadmill.

Instrument the plan so you can correct it. Track four numbers monthly per new hire: credentialed facility count, active surgeon or buyer evaluations opened, qualified pipeline created, and first revenue date. If a rep is at month six with no credentialed facilities, the problem is operational and you can fix it. If they are credentialed everywhere with no evaluations opened, the problem is the rep or the territory and you have five months of runway to act rather than discovering it at the annual review.

Related questions

Should I hire distributors or direct reps first?

Start with distributors when territories are unproven and cash is tight — they cost nothing until they sell. Convert to direct reps once a territory clears roughly $700K–$1M in annual revenue, where a 25–35% commission exceeds a salaried rep's loaded cost and you want the surgeon relationship on your books.

How do I count reps if my product needs case coverage?

Coverage math overrides revenue math. Estimate weekly case hours per active surgeon, divide a rep's realistic 25–30 sellable hours per week by that, and you get the surgeon ceiling per rep. If revenue math says fewer reps, add clinical specialists rather than quota carriers.

What quota should a new medical device rep carry in year one?

Use a ramped schedule tied to your actual ramp length — commonly 0% for the first quarter, then 33%, 66%, and full quota by month ten. Write it into the offer letter. Full quota during ramp is the leading cause of first-year attrition.

How far ahead of my revenue target should I hire?

Add ramp time to average sales cycle. With 9–12 month ramp and a 12-month cycle, reqs should open roughly 18 months before the revenue year. Capital equipment tied to hospital budget cycles needs even more lead time because the buying window opens on their calendar, not yours.

Does adding reps always add revenue?

No. If existing territories are under-penetrated because reps lack selling hours, adding coverage support returns more revenue per dollar than adding quota carriers. Only add reps when territories are genuinely at capacity or geographically uncovered.

FAQ

How do I calculate the exact number of reps I need?

Subtract the recurring consumables and contracted reorder revenue from your goal to isolate net-new. Divide net-new by what a fully ramped rep originates annually at historical attainment — not at quota. Add backfills for expected attrition, then adjust upward for ramp because a first-year hire delivers only a fraction of a rep-year. The arithmetic is simple; the discipline is using honest inputs rather than plan numbers.

What is realistic net-new production per medical device rep?

It varies enormously by category. Consumables and disposables reps in dense territories may originate $1M–$2M of new business annually on top of a large reorder base. Capital equipment reps might close two to six units a year, so the figure swings with average selling price. Use your own three-year history segmented by territory rather than any industry benchmark, and strip out reorder revenue before you compute it.

How long does ramp actually take in medical device sales?

Typically 9 to 12 months, and longer for implantables or anything requiring OR presence. The clock includes product and clinical training, credentialing through each hospital's vendor management system, and the unavoidable months of building surgeon and value-analysis committee trust. Credentialing alone can consume 30–90 days per facility and runs on the hospital's timeline, not yours.

What attrition rate should I plan for?

Plan on 10–20% annual voluntary turnover in device field sales, weighted toward the first eighteen months. On a ten-person team at 15%, that is roughly one and a half backfills a year before any growth hiring. Each backfill restarts a full ramp cycle in a territory that was already producing, which is why the true cost of turnover is the vacancy plus the ramp, not just the recruiting fee.

How do I model consumables versus capital equipment differently?

Separate them completely. Consumables carry 80–95% reorder retention, so most of that revenue recurs without a rep originating it — size reps to the net-new slice only. Capital equipment has no meaningful recurring component within a year and is gated by the hospital's capital budget cycle, so nearly every dollar is net-new and headcount scales close to linearly with the target.

When does adding a clinical specialist beat adding another sales rep?

When your quota carriers are spending 40% or more of their week on case coverage, in-service training, and product education rather than selling. A clinical specialist costs 40–60% less than a quota carrier, can support several territories, and returns selling hours to reps already on payroll — usually a cheaper path to incremental revenue than a new territory hire.

Sources

• https://www.bls.gov/ooh/sales/wholesale-and-manufacturing-sales-representatives.htm — U.S. Bureau of Labor Statistics occupational data for wholesale and manufacturing sales representatives, including medical and technical device sales
• https://www.fda.gov/medical-devices — U.S. FDA Medical Devices center, for device classification and regulatory pathway context that shapes sales cycle length
• https://hbr.org/topic/subject/sales — Harvard Business Review research on sales force sizing, territory design, and quota setting
• https://www.mckinsey.com/industries/life-sciences/our-insights — McKinsey & Company life sciences insights on commercial models and go-to-market strategy in medtech
• https://www.gartner.com/en/sales — Gartner sales research covering territory planning, quota allocation, and sales productivity
• https://www.advamed.org/ — AdvaMed, the medical device industry trade association, for industry structure and commercial practice standards
• https://www.mddionline.com/ — Medical Device and Diagnostic Industry (MD+DI), for medtech commercial and sales-force reporting
• https://www.bcg.com/industries/medical-devices-technology — Boston Consulting Group medical device and technology practice insights on commercial effectiveness

Related on PULSE

• Do I Need a Fractional CRO for My Medical Device Company?
• How Do I Get My Medical Device Reps to Sell Service Contracts?
• How Many Sales Reps Do I Need to Hire for My Medical Courier Company?
• How Many Sales Reps Do I Need to Hire for My Durable Medical Equipment Company?
• How Many Sales Reps Do I Need to Hire for My Medical Billing Company?
• How Many Sales Consultants Do I Need to Hire for My Medical Spa?